How Merck Gets To $51 Billion: Oncology or Vaccines? |
| March 20, 2020 | March 2020 Bond Updates |
|
Merck (NYSE: MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will account for 32% of the company’s total sales in 2020... |
| View more at: https://www.forbes.com/sites/greatspeculations/2020/03/20/how-merck-gets-to-51-billion-oncology-or-vaccines/ |
| Related News |
|